Morphology of bone marrow and immunophenotypic findings in bone marrow and lymph nodes of patients with UCD and iMCD
| . | UCD . | iMCD . | P value . | ||
|---|---|---|---|---|---|
| Number of patients . | n (%)* . | Number of patients . | n (%)* . | ||
| Morphology of BM | |||||
| Normal | 22 | 12 (54.55) | 22 | 5 (22.72) | .004 |
| Abnormal | 22 | 10 (45.45) | 22 | 17 (77.28) | |
| Hypercellular | 22 | 6 (27.27) | 22 | 9 (40.91) | .346 |
| Hypocellular | 22 | 2 (9.09) | 22 | 4 (18.18) | .664 |
| PC infiltration | 22 | 3 (13.64) | 22 | 1 (4.55) | .607 |
| BM fibrosis | 22 | 0 (0) | 22 | 1 (4.55) | 1.000 |
| Megakaryocytic hyperplasia | 22 | 0 (0) | 22 | 2 (9.10) | .489 |
| Single lymphohistiocytic aggregation | 22 | 1 (4.55) | 22 | 3 (13.65) | .607 |
| Increased PCs with polyclonal light chain expression | 22 | 0 (0) | 22 | 1 (4.55) | 1.000 |
| Increased histiocytes with hemophagocytosis | 22 | 0 (0) | 22 | 1 (4.55) | 1.000 |
| Megakaryocytic hyperplasia with reticulin fibrosis | 22 | 0 (0) | 22 | 4 (18.20) | .108 |
| BM cellular immunophenotype (CD45+) | |||||
| CD56+/CD3− | 16 | 16.14 ± 11.26 | 13 | 12.42 ± 9.26 | .662 |
| CD3+ | 14 | 63.28 ± 12.89 | 13 | 65.93 ± 11.66 | .582 |
| CD3+/CD4+ | 13 | 36.32 ± 13.30 | 12 | 35.76 ± 11.64 | .911 |
| CD3+/CD8+ | 13 | 24.27 ± 10.08 | 12 | 29.73 ± 17.86 | .397 |
| CD19+ | 17 | 25.38 ± 21.30 | 15 | 15.48 ± 15.13 | .145 |
| LN cellular immunophenotype (CD45+) | |||||
| CD56+/CD3− | 13 | 1.36 ± 0.95 | 7 | 2.81 ± 3.39 | .159 |
| CD3+ | 18 | 43.19 ± 17.37 | 9 | 58.88 ± 20.57 | .048 |
| CD3+/CD4+ | 14 | 33.80 ± 11.57 | 7 | 40.56 ± 17.47 | .300 |
| CD3+/CD8+ | 14 | 14.34 ± 10.72 | 7 | 12.3 ± 4.942 | .641 |
| CD19+ | 18 | 49.63 ± 17.45 | 9 | 37.13 ± 22.34 | .122 |
| CD19+/CD5+ | 16 | 17.37 ± 15.80 | 11 | 5.88 ± 6.52 | .032 |
| CD19+/κ+ | 18 | 46.66 ± 19.62 | 8 | 43.60 ± 18.28 | .731 |
| CD19+/λ+ | 18 | 37.84 ± 8. 88 | 8 | 44.15 ± 19.61 | .263 |
| CD5+ | 18 | 60.25 ± 12.32 | 8 | 66.48 ± 9.10 | .214 |
| CD10+ | 16 | 2.40 ± 4.08 | 8 | 4.46 ± 3.86 | .249 |
| CD20+ | 18 | 45.95 ± 25.97 | 9 | 39.93 ± 19.49 | .546 |
| CD22+/CD23+ | 17 | 46.83 ± 18.70 | 8 | 49.44 ± 27.03 | .78 |
| FMC7+ | 14 | 21.79 ± 13.02 | 5 | 21.11 ± 15.74 | .925 |
| CD22+ | 12 | 66.78 ± 27.10 | 5 | 72.34 ± 38.58 | .737 |
| CD11c+/CD22+ | 14 | 1.35 ± 1.04 | 6 | 1.80 ± 1.36 | .433 |
| . | UCD . | iMCD . | P value . | ||
|---|---|---|---|---|---|
| Number of patients . | n (%)* . | Number of patients . | n (%)* . | ||
| Morphology of BM | |||||
| Normal | 22 | 12 (54.55) | 22 | 5 (22.72) | .004 |
| Abnormal | 22 | 10 (45.45) | 22 | 17 (77.28) | |
| Hypercellular | 22 | 6 (27.27) | 22 | 9 (40.91) | .346 |
| Hypocellular | 22 | 2 (9.09) | 22 | 4 (18.18) | .664 |
| PC infiltration | 22 | 3 (13.64) | 22 | 1 (4.55) | .607 |
| BM fibrosis | 22 | 0 (0) | 22 | 1 (4.55) | 1.000 |
| Megakaryocytic hyperplasia | 22 | 0 (0) | 22 | 2 (9.10) | .489 |
| Single lymphohistiocytic aggregation | 22 | 1 (4.55) | 22 | 3 (13.65) | .607 |
| Increased PCs with polyclonal light chain expression | 22 | 0 (0) | 22 | 1 (4.55) | 1.000 |
| Increased histiocytes with hemophagocytosis | 22 | 0 (0) | 22 | 1 (4.55) | 1.000 |
| Megakaryocytic hyperplasia with reticulin fibrosis | 22 | 0 (0) | 22 | 4 (18.20) | .108 |
| BM cellular immunophenotype (CD45+) | |||||
| CD56+/CD3− | 16 | 16.14 ± 11.26 | 13 | 12.42 ± 9.26 | .662 |
| CD3+ | 14 | 63.28 ± 12.89 | 13 | 65.93 ± 11.66 | .582 |
| CD3+/CD4+ | 13 | 36.32 ± 13.30 | 12 | 35.76 ± 11.64 | .911 |
| CD3+/CD8+ | 13 | 24.27 ± 10.08 | 12 | 29.73 ± 17.86 | .397 |
| CD19+ | 17 | 25.38 ± 21.30 | 15 | 15.48 ± 15.13 | .145 |
| LN cellular immunophenotype (CD45+) | |||||
| CD56+/CD3− | 13 | 1.36 ± 0.95 | 7 | 2.81 ± 3.39 | .159 |
| CD3+ | 18 | 43.19 ± 17.37 | 9 | 58.88 ± 20.57 | .048 |
| CD3+/CD4+ | 14 | 33.80 ± 11.57 | 7 | 40.56 ± 17.47 | .300 |
| CD3+/CD8+ | 14 | 14.34 ± 10.72 | 7 | 12.3 ± 4.942 | .641 |
| CD19+ | 18 | 49.63 ± 17.45 | 9 | 37.13 ± 22.34 | .122 |
| CD19+/CD5+ | 16 | 17.37 ± 15.80 | 11 | 5.88 ± 6.52 | .032 |
| CD19+/κ+ | 18 | 46.66 ± 19.62 | 8 | 43.60 ± 18.28 | .731 |
| CD19+/λ+ | 18 | 37.84 ± 8. 88 | 8 | 44.15 ± 19.61 | .263 |
| CD5+ | 18 | 60.25 ± 12.32 | 8 | 66.48 ± 9.10 | .214 |
| CD10+ | 16 | 2.40 ± 4.08 | 8 | 4.46 ± 3.86 | .249 |
| CD20+ | 18 | 45.95 ± 25.97 | 9 | 39.93 ± 19.49 | .546 |
| CD22+/CD23+ | 17 | 46.83 ± 18.70 | 8 | 49.44 ± 27.03 | .78 |
| FMC7+ | 14 | 21.79 ± 13.02 | 5 | 21.11 ± 15.74 | .925 |
| CD22+ | 12 | 66.78 ± 27.10 | 5 | 72.34 ± 38.58 | .737 |
| CD11c+/CD22+ | 14 | 1.35 ± 1.04 | 6 | 1.80 ± 1.36 | .433 |
Significant P values are in bold.
BM, bone marrow; LN, lymph node.
Data represent n (%) of patients or median number of cells ± standard error.